The Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) has awarded 2020 FCDGC Pilot Grants to Kent Lai, PhD, and Lan Lin, PhD.
Kent Lai, PhD
Lai is a professor in the Department of Pediatrics at the University of Utah School of Medicine. Lai specializes in therapeutic development and mouse models of inborn errors of metabolism. Lai’s project, “Novel Mouse Models of Human Phosphoglucomutase I Deficiency (PGM1-CDG),” aims to explore the underlying disease mechanisms and lay the foundation for the identification of more effective treatments for PGM1 Deficiency, a congenital disorder of glycosylation (CDG), leveraging a novel and relevant animal model of this debilitating rare disorder.
Lan Lin, PhD
Lin is an assistant professor of pathology and laboratory medicine at the Children’s Hospital of Philadelphia and the University of Pennsylvania. Lin specializes in developing and using genomic approaches to study post-transcriptional RNA processing and modifications in health and disease. Lin’s project, “Discovery of the roles of glycoRNA species in Congenital Disorders of Glycosylation,” aims to explore the expression, biochemical property, and function of N-glycosylated RNA (glycoRNA) species in CDG.
The FCDGC pilot program supports investigator-initiated studies that address translational research in CDG. Lai and Lin will receive $40,000 support for their work.
Congratulations, Lai and Lin!
The Frontiers in Congenital Disorders of Glycosylation Consortium (FCDGC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). FCDGC is funded under grant number U54NS115198 as a collaboration between NCATS, the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the Office of Dietary Supplements (ODS).